Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis

References

• JannePA, YangJC, KimDW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–1699. doi:10.1056/NEJMoa141181725923549
   PubMed Web of Science ®Google Scholar
• ZhangX, ChangA. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet. 2006;44(3):166–172. doi:10.1136/jmg.2006.04610217158592
   PubMed Web of Science ®Google Scholar
• YuHA, ArcilaME, RekhtmanN, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR -mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-224623470965
   PubMed Web of Science ®Google Scholar
• RosellR, CarcerenyE, GervaisR, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X22285168
   PubMed Web of Science ®Google Scholar
• MokTS, WuYL, ThongprasertS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• MokTS, WuY, AhnM, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa161267427959700
   PubMed Web of Science ®Google Scholar
• YuHA, SimaCS, HuangJ, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–351. doi:10.1097/JTO.0b013e31827e1f8323407558
   PubMed Web of Science ®Google Scholar
• OxnardGR, ArcilaME, SimaCS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616–1622.21135146
   PubMed Web of Science ®Google Scholar
• Martinez-MartiA, NavarroA, FelipE. Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Transl Lung Cancer Res. 2019;8:S235–46. doi:10.21037/tlcr.2019.04.2031857948
   PubMed Web of Science ®Google Scholar
• SudaK, MitsudomiT. Drug tolerance to EGFR tyrosine kinase inhibitors in lung cancers with EGFR mutations. Cells. 2021;10(7):1590. doi:10.3390/cells1007159034202566
   PubMed Web of Science ®Google Scholar
• GrabeT, LategahnJ, RauhD. C797S resistance: the undruggable EGFR mutation in non-small cell lung cancer?Acs Med Chem Lett. 2018;9(8):779–782. doi:10.1021/acsmedchemlett.8b0031430128066
   PubMed Web of Science ®Google Scholar
• WuYL, ZhangXC, WangJ, et al. Chinese experts consensus on detection of EGFR gene mutation in non-small cell lung cancer blood. Zhonghua Yi Xue Za Zhi. 2015;95(46):3721–3726.
   Google Scholar
• DouillardJY, OstorosG, CoboM, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–1353.25122430
   PubMed Web of Science ®Google Scholar
• AhnM, HanJ, TsaiC, et al. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays. J Thor Oncol. 2017;12(11):S1771.
   Web of Science ®Google Scholar
• WangJ, ChengY, WuY, et al. MA 11.03 gefitinib as first-line treatment of plasma CtDNA EGFR mutation-positive NSCLC detected by DdPCR: BENEFIT study (CTONG1405). J Thor Oncol. 2017;12(11):S1844. doi:10.1016/j.jtho.2017.09.544
   Web of Science ®Google Scholar
• JyDOUILLARD, OstorosG, CoboM, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Brit J Cancer. 2014;110(1):55–62. doi:10.1038/bjc.2013.72124263064
   PubMed Web of Science ®Google Scholar
• MokT, WuY, LeeJS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21(14):3196–3203. doi:10.1158/1078-0432.CCR-14-259425829397
   PubMed Web of Science ®Google Scholar
• MokT, KimSW, WuYL, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017;35(36):4027–4034. doi:10.1200/JCO.2017.73.925028968167
   PubMed Web of Science ®Google Scholar
• TakahamaT, SakaiK, TakedaM, et al. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016;7(36):58492–58499. doi:10.18632/oncotarget.1130327542267
   PubMed Web of Science ®Google Scholar
• SuKY, TsengJS, LiaoKM, et al. Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. PLoS One. 2018;13(11):e207001. doi:10.1371/journal.pone.0207001
   PubMed Web of Science ®Google Scholar
• GarciaJ, WoznyAS, GeiguerF, et al. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells. Cancer Med. 2019;8:3685–3697.31112372
   PubMed Web of Science ®Google Scholar
• ZhengD, YeX, ZhangMZ, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6(1):20913. doi:10.1038/srep2091326867973
   PubMed Web of Science ®Google Scholar
• OxnardGR, ThressKS, AldenRS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–3382. doi:10.1200/JCO.2016.66.716227354477
   PubMed Web of Science ®Google Scholar
• AhnM, HanJ, TsaiC, et al. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays. J Thorac Oncol. 2017;12(11):S1771.
   Web of Science ®Google Scholar
• JenkinsS, YangJC, RamalingamSS, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1061–1070. doi:10.1016/j.jtho.2017.04.00328428148
   PubMed Web of Science ®Google Scholar
• ZhangX, LiangZ, ChenY, et al. MA06.09 detection of EGFR T790M mutations by four testing platforms in ctDNA from Chinese patients with advanced NSCLC. J Thorac Oncol. 2017;12(11):S1823. doi:10.1016/j.jtho.2017.09.497
   Web of Science ®Google Scholar
• WangZ, ChengY, AnT, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a Phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6:681–690. doi:10.1016/S2213-2600(18)30264-930017884
   PubMed Web of Science ®Google Scholar
• ZhouC, ImamuraF, ChengY, et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR- TKIs in the FLAURA trial. J Clin Oncol. 2019;37(15_suppl):9020. doi:10.1200/JCO.2019.37.15_suppl.9020
   Web of Science ®Google Scholar